Effect of Sacubitril/Valsartan on Exercise-Induced Lipid Metabolism in Patients With Obesity and Hypertension

Sacubitril/valsartan (LCZ696), a novel angiotensin receptor-neprilysin inhibitor, was recently approved for the treatment of heart failure with reduced ejection fraction. Neprilysin degrades several peptides that modulate lipid metabolism, including natriuretic peptides. In this study, we investigat...

Descripción completa

Detalles Bibliográficos
Autores principales: Engeli, Stefan, Stinkens, Rudi, Heise, Tim, May, Marcus, Goossens, Gijs H., Blaak, Ellen E., Havekes, Bas, Jax, Thomas, Albrecht, Diego, Pal, Parasar, Tegtbur, Uwe, Haufe, Sven, Langenickel, Thomas H., Jordan, Jens
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott, Williams & Wilkins 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5753808/
https://www.ncbi.nlm.nih.gov/pubmed/29180454
http://dx.doi.org/10.1161/HYPERTENSIONAHA.117.10224

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5753808/
https://www.ncbi.nlm.nih.gov/pubmed/29180454
http://dx.doi.org/10.1161/HYPERTENSIONAHA.117.10224

Ejemplares similares